118 related articles for article (PubMed ID: 36906970)
1. Discovery of drug targets and therapeutic agents based on drug repositioning to treat lung adenocarcinoma.
Graves OK; Kim W; Özcan M; Ashraf S; Turkez H; Yuan M; Zhang C; Mardinoglu A; Li X
Biomed Pharmacother; 2023 May; 161():114486. PubMed ID: 36906970
[TBL] [Abstract][Full Text] [Related]
2. Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma.
Hu W; Wang G; Chen Y; Yarmus LB; Liu B; Wan Y
Aging (Albany NY); 2020 Aug; 12(16):16514-16538. PubMed ID: 32855362
[TBL] [Abstract][Full Text] [Related]
3. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
4. An integrated analysis of prognostic and immune infiltrates for hub genes as potential survival indicators in patients with lung adenocarcinoma.
Xu Z; Wang S; Ren Z; Gao X; Xu L; Zhang S; Ren B
World J Surg Oncol; 2022 Mar; 20(1):99. PubMed ID: 35354488
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
[TBL] [Abstract][Full Text] [Related]
6. miR-133b inhibits cell proliferation, migration, and invasion of lung adenocarcinoma by targeting CDCA8.
Hu C; Wu J; Wang L; Liu X; Da B; Liu Y; Huang L; Chen Q; Tong Y; Jiang Z
Pathol Res Pract; 2021 Jul; 223():153459. PubMed ID: 33971546
[TBL] [Abstract][Full Text] [Related]
7. Identification of key genes and biological pathways in lung adenocarcinoma via bioinformatics analysis.
Wang Y; Zhou Z; Chen L; Li Y; Zhou Z; Chu X
Mol Cell Biochem; 2021 Feb; 476(2):931-939. PubMed ID: 33130972
[TBL] [Abstract][Full Text] [Related]
8. Integrated bioinformatics analysis reveals CDK1 and PLK1 as potential therapeutic targets of lung adenocarcinoma.
Li S; Li H; Cao Y; Geng H; Ren F; Li K; Dai C; Li N
Medicine (Baltimore); 2021 Aug; 100(32):e26474. PubMed ID: 34397869
[TBL] [Abstract][Full Text] [Related]
9. Integrative analyses identified ion channel genes GJB2 and SCNN1B as prognostic biomarkers and therapeutic targets for lung adenocarcinoma.
Lu A; Shi Y; Liu Y; Lin J; Zhang H; Guo Y; Li L; Lin Z; Wu J; Ji D; Wang C
Lung Cancer; 2021 Aug; 158():29-39. PubMed ID: 34111567
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing based on differentially expressed genes suggests drug combinations with possible synergistic effects in treatment of lung adenocarcinoma.
Yesharim L; Teimourian S
Cancer Biol Ther; 2023 Dec; 24(1):2253586. PubMed ID: 37710391
[TBL] [Abstract][Full Text] [Related]
11. Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways.
Zhang J; Wang X; Song C; Li Q
BMC Cancer; 2023 Feb; 23(1):152. PubMed ID: 36782138
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
13. Identification of hub driving genes and regulators of lung adenocarcinoma based on the gene Co-expression network.
Xu Z; Wu Z; Xu J; Zhang J; Yu B
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32196072
[TBL] [Abstract][Full Text] [Related]
14. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma.
Dai D; Shi R; Han S; Jin H; Wang X
Medicine (Baltimore); 2020 Aug; 99(32):e21478. PubMed ID: 32769881
[TBL] [Abstract][Full Text] [Related]
15. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
16. Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates.
De Bastiani MA; Klamt F
Cancer Med; 2019 Nov; 8(15):6717-6729. PubMed ID: 31503425
[TBL] [Abstract][Full Text] [Related]
17. The potential bioactive ingredients and hub genes of five TCM prescriptions against lung adenocarcinoma were explored based on bioinformatics.
Liu T; Wei J
Naunyn Schmiedebergs Arch Pharmacol; 2023 Sep; 396(9):2039-2055. PubMed ID: 36914901
[TBL] [Abstract][Full Text] [Related]
18. Network module function enrichment analysis of lung squamous cell carcinoma and lung adenocarcinoma.
Li P; Yuan H; Kuang X; Zhang T; Ma L
Medicine (Baltimore); 2022 Nov; 101(47):e31798. PubMed ID: 36451444
[TBL] [Abstract][Full Text] [Related]
19. Identification of target gene and prognostic evaluation for lung adenocarcinoma using gene expression meta-analysis, network analysis and neural network algorithms.
Selvaraj G; Kaliamurthi S; Kaushik AC; Khan A; Wei YK; Cho WC; Gu K; Wei DQ
J Biomed Inform; 2018 Oct; 86():120-134. PubMed ID: 30195659
[TBL] [Abstract][Full Text] [Related]
20. Network Pharmacology and Bioinformatics Analysis Identifies Potential Therapeutic Targets of Paxlovid Against LUAD/COVID-19.
Zhang W; Yang Z; Zhou F; Wei Y; Ma X
Front Endocrinol (Lausanne); 2022; 13():935906. PubMed ID: 36157452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
